Items tagged with Drug-resistant TB

Obama Administration releases National Action Plan for Combating Multidrug-Resistant Tuberculosis (post with simple image)

The White House released a comprehensive action plan identifying a set of targeted interventions that address the core domestic and global challenges posed by multidrug-resistant and extensively drug-resistant tuberculosis.

Urgent need to make linezolid available in South Africa at affordable price (post with simple image)

TB advocates urge pharmaceutical companies to register their respective linezolid products in South Africa and make them available at an affordable price.

TAG’s response to the U.S. Action Plan for Combating Multidrug-Resistant Tuberculosis (post with simple image)

The targets set forth in the Obama Administration’s National Action Plan for Combating Multidrug-Resistant Tuberculosis are not ambitious enough to effectively stop the spread of multidrug-resistant tuberculosis.

Lancet Series on access to and sustainable effectiveness of antimicrobials (post with simple image)

The Lancet published a Series of five papers examining access to and sustainable effectiveness of antimicrobials.

Global pharmaceutical industry calls on governments to work with them to beat the rising threat of antimicrobial resistance (post with simple image)

In a joint declaration more than 80 leading international pharmaceutical, generics, diagnostics and biotechnology companies, as well as key industry bodies, call on governments and industry to work in parallel in taking comprehensive action against antimicrobial resistance.

U.S. Senators appeal to President Obama for TB plan funding (post with simple image)

U.S. Senators send letter urging President Obama to increase funding to allow full implementation of the National Action Plan for Combating Multidrug-Resistant Tuberculosis.  

Global progress and challenges in implementing new medications for treating multidrug-resistant tuberculosis (post with simple image)

Introducing bedaquiline and delamanid in TB programs worldwide has not kept pace with the need for these drugs. Coordinated global action might help assist making these medications accessible for persons who need them most.

Stop TB Partnership's Global Drug Facility jumpstarts access to new drugs for MDR-TB with innovative public-private partnerships (post with simple image)

The initiative will allow countries to access delamanid through the Stop TB Partnership’s Global Drug Facility at a price of US$ 1700 for each full-course treatment of six months’ duration.

Just 2% of people with the severest cases of drug-resistant TB currently have access to new, more effective treatments (post with simple image)

Médecins Sans Frontières released the 4th edition of its report DR-TB Drugs Under the Microscope. The report analyzes the barriers and factors affecting access to treatment regimens for drug-resistant tuberculosis.

Advocates call for WHO to update Delamanid Guidance to include children (post with simple image)

On World TB Day, and in light of new evidence of safety in children, advocates called on the World Health Organization to update its 2014 guidance on delamanid to include children.

Page 59 of 62 · Total posts: 0

←First 58 59 60 Last→